Searched for
DIVIS LABORATORIES
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- More women CXOs join India’s million-dollar pay club as domestic firms lead compensation growthNine women now earn over one million dollars annually as C-suite executives. Domestic companies are leading this rise, reflecting a focus o...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Positive Breakout: These 8 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend.
- Saurabh Mukherjea has moved half his personal portfolio out of India; here's whySaurabh Mukherjea, founder of Marcellus Investment Managers, has shifted his personal portfolio to a 50-50 split between Indian and global ...
- Sell Divi's Laboratories, target price Rs 4,500: ICICI SecuritiesICICI Securities recommends a sell on Divi's Laboratories with a target price of Rs 4,500 despite recent quarterly growth. Management remai...
- Divis Labs shares 0.64% as NiftyA total of 2,625 shares changed hands on the counter till time (IST).
- Divis Labs shares 0.2% as Nifty gainsA total of 2,219 shares changed hands on the counter till 01:18PM (IST).
- Share price of Divis Labs falls as Sensex gains 208.32 pointsPromoters held 51.9 per cent stake in the company as of 30-Jun-2024, while FII and DII ownership stood at 16.16 per cent and 13.1 per cent,...
- Divis Labs shares rise 0.28% as Sensex climbsA total of 2,157 shares changed hands on the counter till 12:27PM (IST)
- Divis Labs shares gain 0.58% as Sensex fallsOn the technical charts, the RSI of the stock stood at 66.95.
- Divis Labs shares decline 2.21% as Sensex slidesA total of 15,796 shares changed hands on the counter till 12:27PM (IST)
- Shares of Divis Labs rise as Nifty dropsOn the technical charts, the 200-day moving average of the stock stood at Rs 3903.31.
- Buy Divi's Laboratories, target price Rs 3742: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 98115.86 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 3762: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 99034.38 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 4130: Religare BrokingPromoters held 51.93 per cent stake in the company as of 30-Jun-2023, while FIIs owned 14.69 per cent, DIIs 21.03 per cent.
Load More
